hVIVO plc (AIM:HVO)

London flag London · Delayed Price · Currency is GBP · Price in GBX
10.77
+0.37 (3.56%)
Jun 5, 2025, 2:03 PM GMT+1
-60.11%
Market Cap 70.76M
Revenue (ttm) 66.22M
Net Income (ttm) 10.65M
Shares Out 680.37M
EPS (ttm) 0.02
PE Ratio 6.71
Forward PE n/a
Dividend 0.00 (1.92%)
Ex-Dividend Date May 15, 2025
Volume 2,115,944
Average Volume 6,157,152
Open 10.19
Previous Close 10.40
Day's Range 10.00 - 10.80
52-Week Range 6.50 - 31.00
Beta 1.05
RSI 30.11
Earnings Date Jun 10, 2025

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and C... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Yamin Khan
Employees 301
Stock Exchange London Stock Exchange AIM
Ticker Symbol HVO
Full Company Profile

Financial Performance

In 2024, hVIVO's revenue was 66.22 million, an increase of 12.87% compared to the previous year's 58.67 million. Earnings were 10.65 million, a decrease of -33.90%.

Financial Statements

News

Cathal Friel to step down as HVivo chairman

Cathal Friel, the co-founder of pharmaceutical services firm HVivo, formerly Open Orphan, is to step down as chairman of the group.

2 months ago - Independent Ireland

Half Year 2024 hVIVO PLC Investor Presentation Transcript

Half Year 2024 hVIVO PLC Investor Presentation Transcript

9 months ago - GuruFocus

Earnings rise 68pc at pharmaceutical services firm Hvivo

Pharmaceutical services firm Hvivo, formerly Open Orphan, has recorded a 67.6pc jump in earnings in the first six months of the year.

9 months ago - Independent Ireland